A5085684588- Reproductive Health and Contraception
- American Constitutional Law and Politics
- Pregnancy and Medication Impact
- Sexual function and dysfunction studies
- Medical History and Innovations
- Reproductive Health and Technologies
University of California, San Francisco
2022-2023
University of Maryland, Baltimore
2023
University of California, Davis
2022-2023
University of California, Los Angeles
2023
Columbia University
2023
Contra Costa Regional Medical Center
2022
ObjectivesIn 2000, the United States’ Food and Drug Administration (FDA) approved mifepristone for medication abortion. In this article, we explore how Risk Evaluation Mitigation Strategy (REMS) criteria specifically impede family physicians’ ability to provide abortion in primary care settings.Study designWe conducted 56 qualitative interviews with a national sample of physicians across US who were not opposed We examined REMS impact abortion.ResultsOf conducted, 23 participants (41%)...
<h3>Purpose:</h3> Medication abortion (MAB) provision by family physicians has the potential to expand access. However, there are documented individual and structural barriers provision. This study investigates how in United States (US) navigate impeding primary care. <h3>Methods:</h3> We conducted a qualitative on experiences of US with MAB recruited participants at national conferences via professional networks. analysis focuses subset who expressed interest providing MAB....
Most family physicians do not provide abortion care, despite an apparent alignment between the defined values of medicine and provision in primary care. This study seeks to understand how themselves perceive relationship their specialty's provision.We conducted in-depth interviews 2019 with 56 who oppose United States. We employed a deductive-inductive content analysis approach memos identify key themes. focuses on participants' beliefs core those relate medicine.Participants identified...